Pfizer Buys Rights To Gene Therapies Under Development By Vivet.
March 21, 2019
The Wall Street Journal (3/20, Roland, Subscription Publication) reports Pfizer will pay up to €560 million ($636 million) to Vivet Therapeutics for the rights to gene therapies that are under development. Pfizer has paid €45 million ($51 million) already...